Lexicon Pharmaceuticals Inc

NASDAQ:LXRX   11:10:03 AM EDT
3.01
-0.09 (-2.90%)
Products

Lexicon Announces FDA Acceptance Of New Drug Application For Sotagliflozin To Treat Heart Failure

Published: 07/27/2022 12:29 GMT
Lexicon Pharmaceuticals Inc (LXRX) - Lexicon Announces FDA Acceptance of New Drug Application for Sotagliflozin to Treat Heart Failure.
Lexicon Pharmaceuticals Inc - FDA Assigned a Standard Review for NDA Filing With a Prescription Drug User Fee Act (pdufa) Target Action Date in May 2023.